BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...EFung Capital , Cash Capital , Cowin Capital Group , Korea Investment Partners , Elite...
BioCentury | Mar 15, 2019
Finance

HaiHe's listing recipe

...PE, CSPC Pharmaceutical, Hillhouse Capital, Chinese Academy of Sciences Venture Capital, Atlas Capital, BioTrack Capital, Elite...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based...
...immunotherapies (see “Alt Neoantigens” ). Atreca Inc. Chief Strategy Officer Tito Serafini told BioCentury that elite...
...the immune system.” Atreca and OncoResponse Inc., two other companies developing cancer therapies based on elite...
BioCentury | Feb 13, 2019
Financial News

HaiHe raises $147M in series B to advance cancer candidates

...Pharmaceutical Group Ltd., Hillhouse Capital, Chinese Academy of Sciences Venture Capital, Atlas Capital, BioTrack Capital, Elite...
BioCentury | Feb 11, 2019
Financial News

HaiHe raises $147M in series B to advance cancer candidates

...Pharmaceutical Group Ltd., Hillhouse Capital, Chinese Academy of Sciences Venture Capital, Atlas Capital, BioTrack Capital, Elite...
BioCentury | Jul 20, 2018
Finance

JOBS Jolt 3.0?

The latest iteration of the JOBS Act could make it easier for biotechs to go public -- and raise more money more quickly -- but that doesn’t necessarily mean the quality of the IPO queue...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...VCs and crossover investors buy the bulk of the deals -- demonstrated once again that elite...
BioCentury | Jun 29, 2018
Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
Items per page:
1 - 10 of 130
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...EFung Capital , Cash Capital , Cowin Capital Group , Korea Investment Partners , Elite...
BioCentury | Mar 15, 2019
Finance

HaiHe's listing recipe

...PE, CSPC Pharmaceutical, Hillhouse Capital, Chinese Academy of Sciences Venture Capital, Atlas Capital, BioTrack Capital, Elite...
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based...
...immunotherapies (see “Alt Neoantigens” ). Atreca Inc. Chief Strategy Officer Tito Serafini told BioCentury that elite...
...the immune system.” Atreca and OncoResponse Inc., two other companies developing cancer therapies based on elite...
BioCentury | Feb 13, 2019
Financial News

HaiHe raises $147M in series B to advance cancer candidates

...Pharmaceutical Group Ltd., Hillhouse Capital, Chinese Academy of Sciences Venture Capital, Atlas Capital, BioTrack Capital, Elite...
BioCentury | Feb 11, 2019
Financial News

HaiHe raises $147M in series B to advance cancer candidates

...Pharmaceutical Group Ltd., Hillhouse Capital, Chinese Academy of Sciences Venture Capital, Atlas Capital, BioTrack Capital, Elite...
BioCentury | Jul 20, 2018
Finance

JOBS Jolt 3.0?

The latest iteration of the JOBS Act could make it easier for biotechs to go public -- and raise more money more quickly -- but that doesn’t necessarily mean the quality of the IPO queue...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...VCs and crossover investors buy the bulk of the deals -- demonstrated once again that elite...
BioCentury | Jun 29, 2018
Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
Items per page:
1 - 10 of 130